An Update of the Morris Animal Foundation Latest Studies

Courtesy of Golden Retriever Club of Illinois

morris animal foundationMonoclonal Antibody Therapy of Canine B-Cell Lymphoma

PROGRESS UPDATE: Lymphoma is one of the most common cancers of dogs, accounting for an estimated 25 percent of all canine cancers. In humans with lymphoma, the use of therapeutic antibodies has led to significant advances in treatment. read more Antibodies are proteins normally produced by the immune system to identify and neutralize foreign substances, such as viruses. These therapeutic antibodies can also be designed to selectively target and kill malignant cancer cells. Although widely used for treatment of lymphoma in people, similar treatments are currently not available for canine patients. Researchers from Colorado State University, the Garden State Cancer Center and Immunomedics Inc. recently developed a therapeutic antibody that effectively kills canine lymphoma cells.

Funded by Morris Animal Foundation, the research team is conducting a clinical trial to evaluate the antibody's safety and effectiveness in dogs with B-cell lymphoma. So far, 10 dogs have received the antibody infusion and have completed the trial. The cancer was temporarily stabilized in three of these dogs. This is significant as lymphoma usually progresses very quickly when no chemotherapy is given or when chemotherapy is no longer effective. Researchers plan to enroll a total of 15 to 18 dogs to test and compare five different antibody dosing levels. If results of this study are favorable, future clinical studies will be designed to assess the efficacy of multiple treatments with therapeutic antibodies, either when used as a single-agent therapy or in combination with conventional chemotherapy. Although all dogs can be affected by this type of cancer, certain breeds, such as Boxers, Rottweilers, Golden Retrievers and Cocker Spaniels, appear to be at greater risk.


twitter1   instagram logo   



By Laws and Code of Ethics


 pacc 911 header cropped

 dreamstime logo